Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Eichhorst

Showing results (31-40 of 120) with videos related to

Pageof 12
Sort By:
American Journal of Hematology|May 29, 2021
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trialOthman Al-Sawaf, Brittany Gentile, Jacob Devine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
TP53 mutation and survival in chronic lymphocytic leukemiaThorsten Zenz, Barbara Eichhorst, Raymonde Busch, et al.
Leukemia & Lymphoma|July 1, 2016
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemiaNadine Kutsch, Raymonde Busch, Jasmin Bahlo, et al.
Leukemia & Lymphoma|November 21, 2015
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemiaDirk Müller, Kirsten Fischer, Peter Kaiser, et al.
Hemasphere|June 15, 2026
EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformationBarbara Eichhorst, Paolo Ghia, Francesc Bosch, et al.
European Journal of Haematology|October 12, 2016
Economic evaluation of chronic lymphocytic leukemia from a hospital management perspectiveFlorian Kron, Nadine Kutsch, Anna Kostenko, et al.
Future Oncology (London, England)|February 22, 2018
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemiaPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Annals of Hematology|June 26, 2023
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study GroupJulia von Tresckow, Nikola Heyl, Sandra Robrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and VenetoclaxMoritz Fürstenau, Jonathan Weiss, Adam Giza, et al.
Cancer|March 21, 2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemiaGeorg Hopfinger, Raymonde Busch, Natali Pflug, et al.
Pageof 12

Showing results (31-40 of 120) with videos related to

Sort By:
Pageof 12
American Journal of Hematology|May 29, 2021
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trialOthman Al-Sawaf, Brittany Gentile, Jacob Devine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
TP53 mutation and survival in chronic lymphocytic leukemiaThorsten Zenz, Barbara Eichhorst, Raymonde Busch, et al.
Leukemia & Lymphoma|July 1, 2016
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemiaNadine Kutsch, Raymonde Busch, Jasmin Bahlo, et al.
Leukemia & Lymphoma|November 21, 2015
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemiaDirk Müller, Kirsten Fischer, Peter Kaiser, et al.
Hemasphere|June 15, 2026
EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformationBarbara Eichhorst, Paolo Ghia, Francesc Bosch, et al.
European Journal of Haematology|October 12, 2016
Economic evaluation of chronic lymphocytic leukemia from a hospital management perspectiveFlorian Kron, Nadine Kutsch, Anna Kostenko, et al.
Future Oncology (London, England)|February 22, 2018
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemiaPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Annals of Hematology|June 26, 2023
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study GroupJulia von Tresckow, Nikola Heyl, Sandra Robrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and VenetoclaxMoritz Fürstenau, Jonathan Weiss, Adam Giza, et al.
Cancer|March 21, 2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemiaGeorg Hopfinger, Raymonde Busch, Natali Pflug, et al.
Pageof 12